ESMO shifts the HER2 antibody landscape 

HER2 may be one of oncology’s oldest drug targets, but it was a centerpiece of this year’s ESMO Congress, returning to the spotlight as one of the hottest testing grounds for next-generation antibody structures. 

The same molecular target that ushered in the age of monoclonal antibody therapies is driving the next wave of innovation across antibody modalities, and the innovation is leading to a step change in patient benefit...